Physician profile

Hope D Shipman

Endocrinology, Diabetes & Metabolism · Houston, TX

NPI 1932170719

$1,703.88

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Valeritas, INC. $284.52 2019
Sanofi-Aventis U.S. LLC $212.20 2019
Astrazeneca Pharmaceuticals LP $155.75 2019
Abbott Laboratories $134.34 2021
Novo Nordisk INC $134.33 2019
Insulet Corporation $85.34 2019
Lilly USA, LLC $85.03 2019
Corcept Therapeutics $69.74 2019
Medtronic Minimed, INC. $64.03 2019
Amgen INC. $50.41 2019
Ibsa Pharma INC. $49.55 2019
Mannkind Corporation $49.30 2019
Shire North American Group INC $47.63 2019
Abbvie INC. $40.81 2019
Amarin Pharma, INC. $39.50 2019
Show all 24 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Hope D Shipman

$1,703.88

in general payments reported 2019-2025

Years
2019-2021
Top company
Valeritas, INC.

https://glasscript.com/doctor/87166/hope-d-shipman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.